¼¼°èÀÇ ¿Á½ÃÅä½Å ½ÃÀå
Oxytocin
»óǰÄÚµå : 1794586
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 276 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

¿Á½ÃÅä½Å ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 5,220¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9,230¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿Á½ÃÅä½Å ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 1¾ï 5,220¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ 2024-2030³â CAGRÀº 8.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ »êÀüÀº CAGR 10.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 830¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »êÈÄ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2,520¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿Á½ÃÅä½Å ½ÃÀåÀº 2024³â¿¡ 2,520¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö 13.7%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3,360¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 4.3%¿Í 8.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿Á½ÃÅä½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Á½ÃÅä½ÅÀÌ ÀÓ»êºÎ °Ç°­°ü¸® ¹× ±âŸ ºÐ¾ß¿¡¼­ Áß¿äÇÑ ¾à¹°ÀÎ ÀÌÀ¯´Â ¹«¾ùÀϱî?

¿Á½ÃÅä½ÅÀº »êºÎÀΰú ÀÇ·á¿¡¼­ ºÐ¸¸ À¯µµ, »êÈÄ ÃâÇ÷ ¿¹¹æ ¹× Ä¡·á, ºÐ¸¸ ½Ã ¹× »êÈÄ Àڱà ¼öÃà º¸Á¶¿¡ ³Î¸® »ç¿ëµÇ´Â ÆéŸÀ̵å È£¸£¸óÀÔ´Ï´Ù. »ê¸ð °Ç°­°ü¸®, ƯÈ÷ ÀúÀÚ¿ø ȯ°æ¿¡¼­ »ê¸ð »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎÀÎ ºÐ¸¸ ÈÄ ÃâÇ÷·Î ÀÎÇÑ »ç¸Á·ü °¨¼Ò¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÀǾàǰÀº Ãâ»ê °á°ú °³¼±ÀÇ Á߿伺 ¶§¹®¿¡ WHOÀÇ Çʼö ÀǾàǰ ¸ñ·Ï¿¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

ÀǾàǰ µî±ÞÀÇ ¿Á½ÃÅä½ÅÀº º¸Åë ÁÖ»ç·Î Åõ¿©µÇ±â ¶§¹®¿¡ ¾ÈÁ¤¼ºÀ» À¯ÁöÇϱâ À§ÇØ ÄݵåüÀÎ º¸°üÀÌ ÇÊ¿äÇÕ´Ï´Ù. º´¿ø, »êºÎÀΰú Áø·á¼Ò, ¼÷·ÃµÈ Ãâ»ê µµ¿ì¹Ì°¡ ÀÖ´Â Áö¹æ º¸°Ç¼Ò¿¡¼­ °¡Àå ¸¹ÀÌ »ç¿ëµË´Ï´Ù. ¿Á½ÃÅä½ÅÀº ÁÖ·Î Àڱà °­Àå È¿°ú·Î ¾Ë·ÁÁ® ÀÖÁö¸¸, »çȸÀû À¯´ë°¨, ½ºÆ®·¹½º Á¶Àý, ÀÚÆó½ºÆåÆ®·³Àå¾Ö ¿¬±¸ µî Çൿ°úÇп¡ ´ëÇÑ ÀÀ¿ë °¡´É¼ºµµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ÀÀ¿ëÀº ¾ÆÁ÷ Ž»öÀûÀ̸ç, Ç¥ÁØÀûÀÎ ÀÓ»ó ½Ç½À¿¡ À̸£Áö ¸øÇß½À´Ï´Ù.

Á¦Çü, À¯Åë, º¸°ü, Á¢±Ù¼º ¹× À¯È¿¼ºÀ» °³¼±Çϱâ À§ÇØ Á¦Çü, À¯Åë, º¸°üÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

Ç¥ÁØ ¿Á½ÃÅä½Å Á¦Á¦¿¡´Â È¿´ÉÀ» À¯ÁöÇϱâ À§ÇØ 2¡É-8¡É¿¡¼­ º¸°üÇØ¾ß ÇÏ´Â ÁÖ»ç¾×ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÀÌ ¿ä±¸»çÇ×Àº ½Å·ÚÇÒ ¼ö ÀÖ´Â ³ÃÀå½Ã¼³ÀÌ ¾ø´Â ³óÃÌ Áö¿ªÀ̳ª ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­´Â ¹®Á¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¿­¿¡ ¾ÈÁ¤ÇÑ Á¦Á¦³ª ÄݵåüÀÎ ÀÇÁ¸µµ¸¦ ³·Ãß´Â ¿Á½ÃÅä½Å À¯»çÁ¦Á¦, ¼³ÇÏ Åõ¿© µî ´ëü Á¦Á¦¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ ³ë·ÂÀ¸·Î´Â Åõ¾à ½Ç¼ö¿Í ¿À¿°À» ÃÖ¼ÒÈ­ÇÏ´Â ´ÜÀ§ ¿ë·® ÇÁ¸®ÇÊµå ½Ã¸°Áö ¹× ÀÚµ¿ ºñȰ¼ºÈ­ Àü´Þ ÀåÄ¡ÀÇ ±â¼ú Çõ½ÅÀ» µé ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î Æ÷Àå µðÀÚÀÎÀº ÇöÀå¿¡¼­ÀÇ »ç¿ë¼ºÀ» Çâ»ó½Ã۰í, ¼¼°è Çù·Â ÀÌ´Ï¼ÅÆ¼ºê´Â ƯÈ÷ »ê¸ð »ç¸Á·üÀÌ ¿©ÀüÈ÷ ³ôÀº »çÇ϶ó »ç¸· À̳² ¾ÆÇÁ¸®Ä«¿Í ¾Æ½Ã¾Æ ÀϺΠÁö¿ª¿¡¼­ °ø±Þ¸ÁÀÇ °­ÀμºÀ» È®´ëÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©µµ °­È­µÇ¾î ¿Á½ÃÅä½Å Á¦Ç°ÀÇ Ç°ÁúÀÌ º¸ÀåµÇ°í ÀÖ½À´Ï´Ù.

¿Á½ÃÅä½ÅÀº ¾îµð¿¡¼­ °¡Àå ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ¾î¶² ÀÌÇØ°ü°èÀÚ°¡ À¯ÅëÀ» ÁÖµµÇϰí Àִ°¡?

¿Á½ÃÅä½ÅÀº º´¿ø ºÐ¸¸º´µ¿, »êºÎÀΰú Ŭ¸®´Ð, »êºÎÀΰú ÀÀ±Þ¼¾ÅÍ¿¡¼­ °¡Àå ¸¹ÀÌ ÀÓ»óÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç ½Ã½ºÅÛ°ú ºñÁ¤ºÎ±â±¸´Â ƯÈ÷ ±¹Á¦ ¿øÁ¶·Î ¸ðÀÚº¸°Ç ÇÁ·Î±×·¥ÀÌ Áö¿øµÇ´Â Áö¿ª¿¡¼­´Â ¹èÆ÷ÀÇ ÁÖ¿ä ÃËÁøÀÚÀÔ´Ï´Ù. °¢±¹ º¸°ÇºÎ´Â Ç¥ÁØ ºÐ¸¸ ÇÁ·ÎÅäÄÝÀÇ ÀϺηΠ»ê¸ð °ü¸® ŰƮ¿¡ ¿Á½ÃÅä½ÅÀ» Æ÷ÇÔ½ÃŰ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

Áö¿ª ¼ö¿ä´Â ÀÓ»êºÎ »ç¸Á·ü °¨¼Ò°¡ °øÁߺ¸°ÇÀÇ ÃÖ¿ì¼± °úÁ¦ÀÎ °³¹ßµµ»ó±¹¿¡¼­ °¡Àå ³ô½À´Ï´Ù. ±×·¯³ª Á¦Ç°ÀÇ Ç°Áú, º¸°ü Á¶°Ç, ÀÇ·á Á¾»çÀÚ ±³À°¿¡ ´ëÇÑ ÆíÂ÷°¡ Àֱ⠶§¹®¿¡ ÃÖÀûÀÇ »ç¿ëÀº ¿©ÀüÈ÷ Á¦ÇÑÀûÀÔ´Ï´Ù. º¸´Ù ¹ßÀüµÈ ÀÇ·á ½Ã½ºÅÛ¿¡¼­´Â ¿Á½ÃÅä½Å »ç¿ëÀÌ ±¤¹üÀ§ÇÏ°í ±ÔÁ¦µÇ¾î ºÐ¸¸ ½Ã¼³ Àüü¿¡¼­ ÀϰüµÈ Á¢±ÙÀÌ °¡´ÉÇÕ´Ï´Ù. Á¦¾àȸ»ç, º¸°ÇºÎ, ±âºÎÀÚ Àڱݿ¡ ÀÇÇÑ º¸°Ç ÇÁ·Î±×·¥Àº ¿©ÀüÈ÷ Á¶´Þ ¹× À¯Åë Àü·«ÀÇ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù.

¿Á½ÃÅä½Å ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

¿Á½ÃÅä½Å ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»êºÎ °Ç°­¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½É Áõ°¡, ÀÀ±Þ »êºÎÀΰú ÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ È®´ë, ¿Ü°úÀû °³ÀÔ¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑµÈ Áö¿ªÀÇ Ãâ»êÀ² Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »êÈÄ ÃâÇ÷À» ÁÙÀ̱â À§ÇÑ ÀÓ»ó ÁöħÀÇ ¾÷µ¥ÀÌÆ®¿Í Á¶»ê»ç ±³À° È®´ë µî »êÈÄ ÃâÇ÷À» ÁÙÀ̱â À§ÇÑ ³ë·ÂÀº Ãâ»ê Ä¡·áÀÇ ÃÖÀü¼±¿¡¼­ ¿Á½ÃÅä½ÅÀÇ ¿ªÇÒÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

ÀúÀÚ¿ø ȯ°æ¿¡¼­ÀÇ Á¢±Ù¼ºÀ» °³¼±ÇÏ´Â ¿­ ¾ÈÁ¤¼º Á¦Á¦ÀÇ °³¹ß·Î ¼ö¿ä°¡ ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ±¹Á¦º¸°Ç±â±¸°¡ Áö¿øÇÏ´Â Á¶´Þ ÇÁ·Î±×·¥Àº °ø±Þ ¹× ǰÁú º¸Áõ ¸ÞÄ¿´ÏÁòÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. ±Ô°Ý ¹Ì´Þ Á¦Ç°À» Á¦°ÅÇϱâ À§ÇÑ ±ÔÁ¦ °³Çõ°ú °¢±¹ÀÇ º¸°ÇÀÇ·á ÇÁ·ÎÅäÄÝ¿¡ ¿Á½ÃÅä½ÅÀÌ ±¤¹üÀ§ÇÏ°Ô Æ÷ÇԵǸ鼭 ¼¼°è ½ÃÀåÀÇ ¼ºÀåÀ» °è¼Ó µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÀûÀÀÁõ(»êÀü, »êÈÄ), À¯Åë ä³Î(º´¿ø ¾à±¹, µå·°½ºÅä¾î À¯Åë ä³Î, ¿Â¶óÀÎ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°è °íÀ¯ÀÇ SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Oxytocin Market to Reach US$152.2 Million by 2030

The global market for Oxytocin estimated at US$92.3 Million in the year 2024, is expected to reach US$152.2 Million by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Antepartum, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$108.3 Million by the end of the analysis period. Growth in the Postpartum segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.2 Million While China is Forecast to Grow at 13.7% CAGR

The Oxytocin market in the U.S. is estimated at US$25.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$33.6 Million by the year 2030 trailing a CAGR of 13.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Oxytocin Market - Key Trends & Drivers Summarized

Why Is Oxytocin a Vital Drug in Maternal Healthcare and Beyond?

Oxytocin is a peptide hormone used extensively in obstetric care to induce labor, prevent and treat postpartum hemorrhage, and assist in uterine contraction during and after childbirth. It plays a critical role in maternal healthcare, particularly in reducing mortality from postpartum bleeding-a leading cause of maternal death in low-resource settings. The drug is included in the WHO’s list of essential medicines due to its significance in improving birth outcomes.

Pharmaceutical-grade oxytocin is typically administered via injection, requiring cold-chain storage to maintain stability. Its usage is most common in hospitals, maternity clinics, and rural health centers with skilled birth attendants. While primarily known for its uterotonic effects, oxytocin has also been investigated for potential applications in behavioral science, including studies on social bonding, stress regulation, and autism spectrum disorders. However, such applications remain exploratory and not yet standard clinical practice.

How Is Formulation, Distribution, and Storage Evolving to Improve Access and Efficacy?

Standard oxytocin formulations include injectable solutions that must be stored between 2°C and 8°C to retain potency. This requirement poses challenges in rural or under-resourced regions lacking reliable refrigeration. As a result, there is increasing interest in heat-stable formulations and alternatives such as oxytocin analogs or sublingual options that reduce cold-chain dependency.

Efforts to improve access include innovations in unit-dose prefilled syringes and auto-disable delivery devices that minimize dosing errors and contamination. New packaging designs are enhancing usability in field settings, while collaborative global initiatives aim to expand supply chain resilience, particularly in sub-Saharan Africa and parts of Asia where maternal mortality remains high. Regulatory frameworks are also being strengthened to ensure the quality of oxytocin products, as substandard formulations have posed safety risks in certain markets.

Where Is Oxytocin Most Widely Used and Which Stakeholders Are Driving Distribution?

Oxytocin sees its highest clinical use in labor wards of hospitals, maternity clinics, and emergency obstetric care centers. Public health systems and non-governmental organizations are key facilitators of distribution, particularly in regions where maternal health programs are supported by international aid. National health ministries often include oxytocin in maternal care kits as part of standard delivery protocols.

Regional demand is highest in developing countries, where maternal mortality reduction is a public health priority. However, inconsistencies in product quality, storage conditions, and healthcare worker training still limit optimal usage. In more developed healthcare systems, oxytocin use is widespread and regulated, with consistent access across birthing facilities. Pharmaceutical companies, health ministries, and donor-funded health programs remain central players in procurement and distribution strategies.

Growth in the Oxytocin market is driven by several factors…

Growth in the oxytocin market is driven by factors such as increasing global emphasis on maternal health, expanded investment in emergency obstetric care, and rising birth rates in regions with limited access to surgical interventions. Efforts to reduce postpartum hemorrhage, including updated clinical guidelines and expanded midwife training, are reinforcing oxytocin's role in frontline childbirth care.

Demand is further supported by development of heat-stable formulations that improve access in low-resource settings. Procurement programs backed by international health organizations are scaling up supply and quality assurance mechanisms. Regulatory reforms to eliminate substandard products, combined with broader inclusion of oxytocin in national health protocols, continue to support market growth globally.

SCOPE OF STUDY:

The report analyzes the Oxytocin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Antepartum, Postpartum); Distribution Channel (Hospital Pharmacies, Drug Stores Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â